Brief Report: The Effectiveness of Osimertinib in Advanced Nonsmall Cell Lung Cancer Harboring Various EGFR Exon 19 Mutation Variants.
Journal
Clinical lung cancer
ISSN
1938-0690
Date Issued
2025-03-21
Author(s)
Abstract
No significant difference in progression-free survival and overall survival with osimertinib was observed between E746del (deletions starting at codon E746) and L747del (deletions starting at codon L747) mutations. • EGFR exon 19 non-LRE deletions, which do not include the entire LRE fragment, may be linked to a poorer prognosis in patients receiving osimertinib treatment. • Rare EGFR exon 19 mutations demonstrated diverse responses to osimertinib.
Subjects
Deletion in exon 19
Epidermal growth factor receptor
Rare EGFR mutation
Survival outcomes
Targeted therapy
SDGs
Type
journal article